[Clinical experience with intravenous administration of nifekalant hydrochloride for ventricular tachycardia in a hemodialysis patient after open heart surgery]

Kyobu Geka. 2010 Oct;63(11):988-91.
[Article in Japanese]

Abstract

A 78-year-old man with chronic renal failure (CRF) on hemodialysis (HD) was diagnosed as having severe aortic regurgitation with left ventricular dysfunction. Aortic valve replacement with a 21 mm ATS mechanical bileaflet prosthesis was performed without intraoperative complications. Sustained ventricular tachycardia suddenly occurred 1 day after surgery, then intravenous administration of nifekalant hydrochloride (NIF) was started at a dose of 0.40 mg/kg/hr. Life-threating ventricular arrhythmia was controlled, hemodynamic compromise was improved dramatically. NIF was regulated with a low-dose of 0.24 mg/kg/hr to prevent malignant side effect such as torsa de pointes. Since QTc was elongated to 0.57 seconds 11 hours after administration, NIF was stopped. Low-dose intravenous administration of NIF in patients with CRF on HD could be useful to prevent ventricular tachyarrhythmias without any adverse effect after cardiac surgery.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Anti-Arrhythmia Agents / therapeutic use*
  • Aortic Valve / surgery*
  • Heart Valve Prosthesis
  • Hemodialysis Solutions
  • Humans
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / therapy
  • Male
  • Postoperative Complications
  • Pyrimidinones / therapeutic use*
  • Tachycardia, Ventricular / drug therapy*

Substances

  • Anti-Arrhythmia Agents
  • Hemodialysis Solutions
  • Pyrimidinones
  • nifekalant